The live registry could not be reached. This stored record may be out of date, and its Actual/Estimated date labels are unavailable. Check ClinicalTrials.gov for current information.

ClinicalTrials.gov record

Active, not recruiting Phase 1 Interventional

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

ClinicalTrials.gov ID: NCT04109729

Public ClinicalTrials.gov record NCT04109729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Aug 4, 2026, 8:31 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.

Study identification

NCT ID: NCT04109729
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: University of Utah; Other
Enrollment: 39 participants

Conditions and interventions

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

Nivolumab Drug
Radium-223 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 16, 2020 (Type not available)
Primary completion: Apr 28, 2026 (Type not available)
Completion: Dec 2026 (Type not available)
Last update posted: Jun 1, 2026

2020 – 2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Huntsman Cancer Institute at University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04109729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 1, 2026 · Synced Aug 4, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04109729 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →